Furthermore, ALK-resistance mutations and an EMT component can simultaneously co-exist in two different tumor cell subpopulations in patients with ALK-rearranged NSCLC who are resistant to crizotinib [10,36]. This evidence concerns the gene ALK and neoplasm.